Cytokinetics, Inc.

500 articles with Cytokinetics, Inc.

• Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction

  6/15/2021

  Cytokinetics, Incorporated today announced the completion of patient enrollment in METEORIC-HF the second Phase 3 clinical trial of omecamtiv mecarbil.

• Cytokinetics to Participate in Upcoming Investor Conferences - June 02, 2021

  6/2/2021

  Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in three virtual fireside chats at the following investor conferences:.

• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2021

  6/1/2021

  Cytokinetics, Incorporated announced that on May 31, 2021 it granted stock options to purchase an aggregate of 49,500 shares of common stock to eight new employees whose employment commenced in May 2021 as a material inducement to their employment.

• Cytokinetics Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 70th Annual Scientific Session and Published in the Journal of American College of Cardiology

  5/17/2021

  Analysis Shows Treatment Effect of Omecamtiv Mecarbil Increased Progressively as Baseline Ejection Fraction Decreased

• Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)

  5/16/2021

  Cytokinetics, Incorporated announced that new findings from analyses of claims data and electronic health records related to heart failure and hypertrophic cardiomyopathy were shared in two poster presentations at the American College of Cardiology 70th Annual Scientific Session & Expo.

• Cytokinetics Announces Three Upcoming Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session

  5/10/2021

  Secondary Analysis From GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session

• Cytokinetics Reports First Quarter 2021 Financial Results

  5/6/2021

  Cytokinetics, Incorporated reported financial results for the first quarter of 2021. Net loss for the first quarter was $47.1 million, or $0.66 per share, compared to net loss for the first quarter of 2020 of $39.4 million, or $0.66 per share.

• Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing REDWOOD-HCM

  5/6/2021

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first site has been activated to enroll patients in REDWOOD-HCM OLE, an open-label extension clinical study designed to assess the long-term safety and tolerability of CK-3773274 (CK-274) in patients with symptomatic obstructive HCM (oHCM). Eligible patients have completed participation in REDWOOD-HCM, the Phase 2 clinical trial of CK-274,

• Cytokinetics to Hold Annual Meeting of Stockholders - May 05, 2021

  5/5/2021

  Cytokinetics, Incorporated announced that its Annual Meeting of Stockholders will be held on Wednesday, May 12, 2021 at 10:30 AM Pacific Time at the Company’s headquarters, 280 East Grand Avenue, South San Francisco, CA.

• Cytokinetics Announces Cohort 3 of REDWOOD-HCM is Open to EnrollmentNext Cohort to Enroll Patients on Background Therapy of Disopyramide

  5/4/2021

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 3 of REDWOOD-HCM ( R andomized E valuation of D osing W ith CK-274 in O bstructive O utflow D isease in HCM ), an ongoing Phase 2 clinical trial of CK-3773274 (CK-274), a next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM).

• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2021

  5/3/2021

  Cytokinetics, Incorporated announced that on April 30, 2021 it granted stock options to purchase an aggregate of 69,800 shares of common stock to six new employees whose employment commenced in April 2021 as a material inducement to their employment.

• 

  Astellas Pulls the Plug on R&D Partnership with Cytokinetics

  5/3/2021

  One year after Astellas and California-based Cytokinetics extended an agreement to develop Skeletal Sarcomere Activators, the Japanese pharma company is walking away from the deal.

• Cytokinetics to Announce First Quarter Results on May 6, 2021

  4/22/2021

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 6, 2021 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future.

• Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Chemical Society Spring 2021 Virtual Meeting

  4/12/2021

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data related to the optimization of CK-3773274 (CK-274), including the first disclosure of its chemical structure, were presented at the American Chemical Society Spring 2021 Virtual Meeting.

• Cytokinetics to Participate in the 20th Annual Needham Virtual Healthcare Conference

  4/5/2021

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 20 th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 3:00 PM ET.

• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2021

  4/1/2021

  Cytokinetics, Incorporated announced that on March 31, 2021 it granted stock options to purchase an aggregate of 163,700 shares of common stock to three new employees, whose employment commenced in March 2021, as a material inducement to their employment.

• Cytokinetics Announces Secondary Analysis From GALACTIC-HF to Be Presented in Late Breaking Clinical Trial Session at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)

  3/18/2021

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF ( G lobal Approach to Lowering A diverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship to patient baseline ejection fraction will be presented in a Late Breaking Clinical Trial session

• Cytokinetics to Participate in Upcoming Investor Conferences - Mar 02, 2021

  3/2/2021

  Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021 and participate in a fireside chat at the virtual Barclays Global Healthcare Conference on March 11, 2021 at 9:45 AM ET.

• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 26, 2021

  2/26/2021

  Cytokinetics, Incorporated announced that on February 26, 2021 it granted stock options to purchase an aggregate of 9,000 shares of common stock to Wing Keung Chiu, a new employee whose employment commenced in February 2021 as a material inducement to his employment.

• Cytokinetics Reports Fourth Quarter 2020 Financial Results

  2/25/2021

  Cytokinetics, Incorporated reported financial results for the fourth quarter and full year 2020. Net loss for the fourth quarter was $43.9 million or $0.62 per share and the net loss for the year 2020 was $127.3 million or $1.97 per share.